Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$153.36
-1.9%
$146.41
$60.00
$200.00
$6.15B-1.23177,970 shs172,384 shs
Erasca, Inc. stock logo
ERAS
Erasca
$19.11
-1.2%
$15.44
$1.33
$24.28
$5.94B0.665.70 million shs3.18 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$90.27
-2.3%
$81.57
$23.30
$105.47
$5.62B2.111.49 million shs1.05 million shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$8.32
-1.1%
$7.30
$4.87
$10.08
$1.44B0.622.23 million shs1.18 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.00%+2.19%+2.36%-4.90%+146.12%
Erasca, Inc. stock logo
ERAS
Erasca
0.00%-0.31%+27.83%-11.06%+1,017.54%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%-3.81%-6.60%+48.13%+150.54%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
0.00%-5.45%+12.43%+37.52%+62.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$153.36
-1.9%
$146.41
$60.00
$200.00
$6.15B-1.23177,970 shs172,384 shs
Erasca, Inc. stock logo
ERAS
Erasca
$19.11
-1.2%
$15.44
$1.33
$24.28
$5.94B0.665.70 million shs3.18 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$90.27
-2.3%
$81.57
$23.30
$105.47
$5.62B2.111.49 million shs1.05 million shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$8.32
-1.1%
$7.30
$4.87
$10.08
$1.44B0.622.23 million shs1.18 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.00%+2.19%+2.36%-4.90%+146.12%
Erasca, Inc. stock logo
ERAS
Erasca
0.00%-0.31%+27.83%-11.06%+1,017.54%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%-3.81%-6.60%+48.13%+150.54%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
0.00%-5.45%+12.43%+37.52%+62.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
2.88
Moderate Buy$203.0032.37% Upside
Erasca, Inc. stock logo
ERAS
Erasca
2.64
Moderate Buy$21.6413.22% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$90.300.03% Upside
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
2.57
Moderate Buy$10.8029.81% Upside

Current Analyst Ratings Breakdown

Latest XERS, BLTE, ERAS, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/23/2026
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
UpgradeSell (D+)Hold (C-)
7/22/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Reiterated RatingBuy
7/20/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
UpgradeHoldStrong-Buy
7/20/2026
Erasca, Inc. stock logo
ERAS
Erasca
Boost Price TargetEqual Weight$12.00 ➝ $21.00
7/16/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$110.00
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Reiterated RatingBuy
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Set Price Target$24.00
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Set Price Target$20.00
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Reiterated RatingBuy
7/14/2026
Erasca, Inc. stock logo
ERAS
Erasca
Boost Price TargetNeutral$16.00 ➝ $18.00
7/14/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$90.00 ➝ $120.00
(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$20.54 per shareN/A
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/A$1.05 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M14.93N/AN/A$7.84 per share11.51
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$291.85M4.92$0.10 per share83.06$0.08 per share104.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$77.61M-$2.53N/AN/AN/AN/A-13.14%-12.88%8/10/2026 (Estimated)
Erasca, Inc. stock logo
ERAS
Erasca
-$124.55M-$0.93N/AN/AN/AN/A-35.31%-29.49%8/11/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$550K$0.06138.6725.21N/A3.81%735.00%3.24%8/6/2026 (Estimated)

Latest XERS, BLTE, ERAS, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Erasca, Inc. stock logo
ERAS
Erasca
-$0.12N/AN/AN/AN/AN/A
8/10/2026Q2 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.73N/AN/AN/AN/AN/A
8/6/2026Q2 2026
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$0.02N/AN/AN/A$90.13 millionN/A
8/3/2026Q3 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.50N/AN/AN/A$114.55 millionN/A
5/15/2026Q1 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.60-$0.34+$0.26-$0.68N/AN/A
5/11/2026Q1 2026
Erasca, Inc. stock logo
ERAS
Erasca
-$0.1150-$0.60-$0.4850-$0.60N/AN/A
5/7/2026Q1 2026
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.0027$0.01+$0.0127$0.01$79.83 million$83.13 million
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
33.71
33.71
Erasca, Inc. stock logo
ERAS
Erasca
N/A
9.52
9.52
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
17.00
2.12
1.50

Institutional Ownership

CompanyInstitutional Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.53%
Erasca, Inc. stock logo
ERAS
Erasca
67.78%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
13.29%
Erasca, Inc. stock logo
ERAS
Erasca
14.20%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
4.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
1040.08 million34.76 millionNot Optionable
Erasca, Inc. stock logo
ERAS
Erasca
120310.98 million266.83 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
290172.64 million165.13 millionOptionable

Recent News About These Companies

Xeris Announces Updates to Its Board of Directors

New MarketBeat Followers Over Time

Media Sentiment Over Time

Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$153.36 -2.92 (-1.87%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$153.10 -0.26 (-0.17%)
As of 07/24/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Erasca stock logo

Erasca NASDAQ:ERAS

$19.11 -0.23 (-1.19%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$19.23 +0.12 (+0.64%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$90.27 -2.17 (-2.35%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$90.22 -0.05 (-0.06%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$8.32 -0.09 (-1.07%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$8.37 +0.05 (+0.60%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.